Literature DB >> 22515126

Extravasation of pegylated-liposomal doxorubicin: favorable outcome after immediate subcutaneous administration of corticosteroids.

Ayako Mitsuma1, Masataka Sawaki, Takashi Shibata, Sachi Morita, Megumi Inada, Tomoya Shimokata, Mihoko Sugishita, Koichi Kitagawa, Masaki Sawada, Akihiro Nawa, Yuichi Ando.   

Abstract

A massive extravasation of pegylated-liposomal doxorubicin (Doxil) accidentally occurred, affecting the right forearm of a 54-year-old woman with metastatic ovarian cancer who was receiving an intravenous infusion of the drug. In accordance with the institutional guidelines for vesicant drugs, a corticosteroid preparation was immediately injected subcutaneously into the surrounding tissues. Clobetasol propionate and an ice pack were then topically applied to the affected region. There were no serious complications at the extravasation site, such as tissue necrosis or severe pain, and only a transient erythema of the skin and desquamation remained after 2 months.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22515126      PMCID: PMC4831265     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  4 in total

1.  Doxil extravasation injury: a case report.

Authors:  J Lokich
Journal:  Ann Oncol       Date:  1999-06       Impact factor: 32.976

2.  Lack of vesicant injury following extravasation of liposomal doxorubicin.

Authors:  S Madhavan; D W Northfelt
Journal:  J Natl Cancer Inst       Date:  1995-10-18       Impact factor: 13.506

3.  Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.

Authors:  G Bertelli; A Gozza; G B Forno; M G Vidili; S Silvestro; M Venturini; L Del Mastro; O Garrone; R Rosso; D Dini
Journal:  J Clin Oncol       Date:  1995-11       Impact factor: 44.544

4.  Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results.

Authors:  G Bertelli; D Dini; G B Forno; A Gozza; S Silvestro; M Venturini; R Rosso; P Pronzato
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.